Live Breaking News & Updates on Mei Pharma Inc

Stay updated with breaking news from Mei pharma inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

MEI Pharma (MEIP) Reports Initial Data from Study of ME-344 in Combination with Bevacizumab

MEI Pharma (MEIP) Reports Initial Data from Study of ME-344 in Combination with Bevacizumab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Davida Walsey , David Urso , Richard Ghalie , Mei Pharma Inc , Pharma Inc , Academic Gi Cancer Consortium , Clinical Study Protocol , Bevacizumab Combination , Initial Safety , Initial Efficacy , Private Securities Litigation Reform Act ,

MEI Pharma (MEIP) Board Aligns on Strategy to Advance Voruciclib and ME-344

MEI Pharma (MEIP) Board Aligns on Strategy to Advance Voruciclib and ME-344
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David Urso , Taheer Datoo , Davida Walsey , Company Board Of Directors , Mei Pharma Inc , Pharma Inc , Cable Car Capital , Anson Funds , Clinical Study , Private Securities Litigation Reform Act ,

MEI Pharma (MEIP) Reports Update from Clinical Study of Voruciclib in Combination with Venetoclax

MEI Pharma (MEIP) Reports Update from Clinical Study of Voruciclib in Combination with Venetoclax
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Yesid Alvarado Valero , Richard Ghalie , Davida Walsey , Department Of Leukemia , University Of Texas Md Anderson Cancer Center , Safety Review Committee , Pharma Inc , Mei Pharma Inc , Associate Professor , Cancer Center , Plus Venetoclax Combination , Initial Safety , Initial Efficacy , Private Securities Litigation Reform Act ,

MEI Pharma (NASDAQ:MEIP) Stock Price Crosses Below 200-Day Moving Average of $6.02

MEI Pharma, Inc. (NASDAQ:MEIP – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.02 and traded as low as $4.25. MEI Pharma shares last traded at $4.26, with a volume of 17,436 shares trading hands. Analysts Set New Price Targets A […] ....

Stifel Nicolaus , Mei Pharma Inc , Simplex Trading , Pharma Inc , National Bank , Get Free Report , Street Group ,

Investment Analysts' Weekly Ratings Changes for MEI Pharma (MEIP)

Several analysts have recently updated their ratings and price targets for MEI Pharma (NASDAQ: MEIP): 2/14/2024 – MEI Pharma had its price target lowered by analysts at Stifel Nicolaus from $8.00 to $7.00. They now have a “hold” rating on the stock. 2/13/2024 – MEI Pharma was downgraded by analysts at StockNews.com from a “buy” […] ....

Stifel Nicolaus , National Bank , Pharma Inc , Simplex Trading , Pharma Inc Daily , Stock Down , Street Group , Inc Daily , Mei Pharma Inc , Nasdaq Meip ,